US EditionPublished • loading... • Updated
Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology
Summary by Helena Independent Record
14 Articles
14 Articles
Montana Standard+13 Reposted by 13 other sources
Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology
DOVER, Del., Nov. 4, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to developing best-in-class and first-in-class small-molecule therapies targeting genetic escape mutations in cancer and advancing innovative treatments for chronic inflammatory and immune diseases, today announced the…
Coverage Details
Total News Sources14
Leaning Left0Leaning Right0Center5Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
